NATIONAL COLLEGE OF PHARMACY MANASSERY FIRST SESSIONAL EXAMINATION SUB:INDUSTRIAL PHARMACY

Date:- 22/11/2023 Time:3Hrs Max Marks:-75 Semester: VII

Answer all questions

SI. No	Question	CO addressed	Marks
1	Write a note on drug development teams and their functions	CO-3	10
2	Discuss pilot plant scale up consideration for tablets	CO-1	10
3	Space requirement and personal requirement.	CO-1	5
4	Explain SUPAC and GMP considerations.	CO-1	5
5	Write a note on IB.	CO-3	5
6	Organisation and functions of CDSCO	CO-4	5
7	Method in data presentation for FDA submission	CO-3	5
8	Explain in detail about COPP	CO-4	5
9	Discuss general consideration of INDA	CO-3	5
10	Write the advantages and disadvantages of pilot plant.	CO-1	2
11	Platform technology.	CO-1	2
12	State licencing authority.	CO-4	2
13	Various modules in CTD	CO-4	2
14	List out pilot plant scale up consideration for semisolids.	CO-1	2
15	Difference between pilotplant and scale up.	CO-1	2
16	Mention the major regulatory bodies in the world.	CO-3	2
17	Clinical research protocol.	CO-3	2
18	Define pre exhibit batch and exhibit batch	CO-1	2
19	What is regulatory affair? What is its goal.	CO-3	2

TANO KOZHIKODE KOZHIKODE KOZHIKODE KOZHIKODE KOZHIKODE

PRINCIPAL
National College of Pharm
Manassery, Kozhikeaa

NATIONAL COLLEGE OF PHARMACY MANASSERY FIRST SESSIONAL EXAMINATION

SUB: NOVEL DRUG DELIVERY SYSTEM

Date:- 27/11/2023

Time: 3Hrs

Max Marks:-75 Semester: VII

Answer all questions

SI.	Question	CO addressed	Marks
No I	Explain the concept of controlled drug delivery system and approaches to design them.	CO-1	10
2	Formulation and evaluation of bioadhesive drug delivery systems	CO-2	10
3	Discuss the formulation criteria for pulmonary route of drug administration.	CO-3	5
4	Theories of mucoadhesion	CO-2	5
5	Classify Polymers in novel drug delivery system	CO-1	5
6	Basic component of osmotic pump	CO-2	5
7	Formulation of nebulizers	CO-3	5
8	Buccal patches	CO-2	5
9	Discuss the limitations of conventional ocular delivery	CO-3	5
10	List out characteristics of ideal polymer	CO-1	2
11	Ocusert	CO-5	2
12	What are implants. Give example.	CO-2	2
13	Enlist ideal features of permeation enhancers with examples.	CO-2	2
14	Mucoadhesive polymers	CO-2	2
15	What is pulmonary DDS? Write about its advantages and disadvantages	CO-3	2
16	Name different mechanisms of drug release from polymers.	CO-1	2
17	Mention two examples each of hydrophilic and hydrophobic polymer.	CO-1	2
18	Name any two ion exchange resins used in controlled drug delivery formulations.	CO-1	2
19	Buccal tablets	CO-2	2

KOZHIKODE 673602

MANASSER

National College of Pharmas, Manassery, Kozhikode

NATIONAL COLLEGE OF PHARMACY, MANASSERY SECOND SESSIONAL EXAMINATION

SUB: BIOPHARMACEUTICS AND PHARMACOKINETICS

Date: 27.01.2023

Max Marks: 75

Time: 3 HOURS


Answer all questions

Semester: VI

SL. No	Question	CO addressed	Marks
1	Explain the kinetics of two compartment open model IV bolus administration.	C0-4	10
2	Explain the urinary excretion method for determining Ke and K _E .	CO-3	10
3	Explain the methods for the enhancement of bioavailability.	CO-2	5
4	Elaborate on in-vitro in-vivo correlation.	CO-2	5
5	Explain the method of residuals to determine the absorption rate constant for a drug. Which follows one compartment open model extravascular administration.	CO-3	5
6	Describe the pharmacokinetics of intravenous multiple dosage regime – one compartment open model.	CO-4	5
7	Elaborate on the compartment models and their types	CO-3	5
8	Describe the Wagnor Nelson method for the calculation of Ka.	CO-2	5
9	Explain the methods available for determining bioavailbility.	CO-2	5
10	Explain any method for determination of AUC.	CO-3	2
11	Explain the key features of any one official apparatus for dissolution studies.	CO-2	2
12	Describe any two pharmacokinetic parameters.	CO-3	2
13	Explain loading dose and maintenance dose.	CO-4	2
14	Explain absolute and relative bioavailability.	CO-2	2
15	Describe flip flop phenomenon.	CO-3	2
16	Explain typical plasma concentration time profile.	CO-3	2
17	Differentiate between compartment modelling and physiological modeling	CO-3	2
18	Explain non-compartmental analysis.	CO-3	2
19	Explain the criteria for establishing valid urinary excretion data.	CO-3	. 2

COLLEGE DE ALLER ACY NE

PRINCIPAL
National College of Pharmacy
Manassery, Kozhikode



Approved by Pharmacy Council of India, AICTE, DME & Govt of Kerala Affiliated to Kerala University of Health Sciences, Accredited by NBA

NATIONAL COLLEGE OF PHARMACY SECOND SEMESTER SECOND SESSIONAL EXAMINATION BIOCHEMISTRY

Date: - 29/11/2023

Max Marks:-75

Time:- 3Hrs


Answer all questions

SI. No	Question	CO addressed	Marks
E	Analyze the biosynthesis of purine ribonucleotides, evaluate the key steps involved, and synthesize the significance of this process.	CO-1	10
2	Explain in detail on different types of enzyme inhibition.	CO-2	10
3	Describe isoenzymes, evaluate their functions.	CO-2	5
4	Explain briefly on Genetic code	CO-4	5
5	Examine the Electron Transport Chain (ETC) with suitable diagrams.	CO-3	5
6	Define and classify enzymes, providing examples for each class, Analyze their functions	CO-2	5
7	Examine the structure of DNA and analyze its functions in genetic information storage and transfer.	CO-4	5
8	Analyze the process of transcription, evaluate its key steps, and synthesize its significance in gene expression.	CO-4	5
9	Examine the structure and functions of ATP, evaluate its role as a cellular energy currency, and synthesize its importance.	CO-3	5
10	Describe any two properties of enzymes	CO-2	2
11	Evaluate substrate-level phosphorylation	CO-3	2

KOZHIKODE 673602

Sign Warms

KMCT Medical College Campus, Manassery, P.O. MukkamPh:-04952297440,Email: pharmacy@kgitt.edu.in,www.nabonalcollegeoipharthacy.org a Cy National College Manassery, Kozhikode



Approved by Pharmacy Council of India, AICTE, DME & Govt of Kerala Affiliated to Kerala University of Health Sciences, Accredited by NBA

12	Examine the Michaelis-Menten equation suitable graph	CO-3	2
13	Explain redox potential	CO-3	2
14	Explain hyperuricemia and gout	CO-1	2
15	Explain about inhibitors of oxidative phosphorylation	CO-3	2
16	Explain on free energy	CO-3	2
17	Analyze the properties of enzymes, evaluate their characteristics, and synthesize their role in catalyzing biochemical reactions.	CO-2	2 .
18	Describe enzyme induction and repression,	CO-2	2
19	Examine the process of DNA replication,	CO-4	2

OVEGE OF ARTHURAS

PRINCIPAL
National College of Pharmacy
Manassery, Kozhikode

			Max M.		500	000	1	1			-		-		1									1			25	53.	Kode		-
		Examination		Marks Awarded	C04	5.0	2		-	7:5	2:2	4.5	11	7.5			1-5	7	2		7	1 .	5.0	5.0	8.4			100	NCIPAL PA	Meg Kori	1105
		Second Sessional Examination		Marks	C03			2.0	2																3.0	valuators		+	XUN WOLLPAL MINOCH	3	P. CHAL.
(317)		Seco			C02							4.0			I				0	, ,	4				9.5	Name & Signature of Evaluators	110		1	-//	1
AADM TUROUS	44				C01		5-1																		5.1	Name &	E OF PL	A. C.	KOZHIKOOK STORY	1	100
M TUE	D. F. HARIM I HEORY	Date		- Questions -		ō	025	03	8	909	90	70	0.8	60	010	110	012	013	014	2 015	0.16	017	018	019	Total Marks	7	1 200	21/10/1	10×		1.00
DAMO A	יייייייייייייייייייייייייייייייייייייי	10		COR	200										-						No.					tal	N			V D IV DE	
		Max Marks		C05																					-	Grand Total	27				
	mination		warded	C04								1								1	The state of the s		1		1		100				
	First Sessional Examination		Marks Awarded	C03	80		2.5	0	K		2.5	×)	2				1	12	200	10	4		28	latore	0			l l		
	First			C02	A STORES	The state of		147		4						2	2						2.	<u> </u>	Name & Signature of Evaluators			1	: 4 to 3	7	
1	1			201	1	0				1			1.5		2							24		1.5	Name & Sic				nal Marks		
		Date:	Constions	-	5	05	03	04	0.55	98	70	80	60	010	011	012	013	014	015	016	017	018	019	Total Marks		1)	2)	0	Signature of Student		